预约演示
更新于：2025-04-25
Lidocaine/Prilocaine
复方利多卡因
更新于：2025-04-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H42N4O2 |
InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N |
CAS号101362-25-8 |
关联
244
项与 复方利多卡因 相关的临床试验NCT06913855
The Effects of EMLA Cream and Cold Application on Pain, Fear and Vital Signs Before Chest Tube Removal in Children: a Randomized Controlled Trial
CTRI/2025/03/081845
A multicenter, randomized, double blind, placebo-controlled, three-arm, prospective, Phase 3 study to evaluate the efficacy, safety, and tolerability of IMP1 and IMP2, potentized formulations, in the treatment of patients with Hypothyroidism. - Nil
CTR20250348
利丙双卡因乳膏人体生物等效性研究
100 项与 复方利多卡因 相关的临床结果
登录后查看更多信息
100 项与 复方利多卡因 相关的转化医学
登录后查看更多信息
100 项与 复方利多卡因 相关的专利（医药）
登录后查看更多信息
1,092
项与 复方利多卡因 相关的文献（医药）2025-05-01MUSCLE & NERVE
Myofascial Pain Syndrome: An Update on Clinical Characteristics, Etiopathogenesis, Diagnosis, and Treatment
Review
作者: Steen, Jeremy P. ; Kumbhare, Dinesh ; Jaiswal, Kishore S.
ABSTRACT:
Myofascial pain syndrome (MPS) is a chronic regional pain condition characterized by trigger points—hyperirritable spots within taut bands of muscle fibers that cause both localized and referred pain. The pathogenesis, diagnostic criteria, and classification of MPS are still under investigation, which complicates the development of standardized treatment protocols. Although diagnostic tools have improved, MPS often remains underrecognized due to symptom overlap with other pain disorders, such as fibromyalgia, neuropathic pain, and joint disorders. Factors contributing to its onset and persistence include muscle overuse, postural imbalance, systemic conditions, and psychological and behavioral influences. This narrative review explores the primary risk factors, current hypotheses on pathogenesis, diagnosis and differential diagnosis, and both conventional and emerging treatments. Sufficient evidence supports the use of local anesthetic injections for MPS. Some evidence suggests that dry needling, acupuncture, magnetic stimulation, ultrasound therapy, laser therapy, extracorporeal shock wave therapy, and manual therapy may be effective, particularly compared to sham or placebo. However, non‐steroidal anti‐inflammatory drugs, diclofenac, botulinum toxin, and transcutaneous electrical nerve stimulation show insufficient evidence, while the effectiveness of muscle relaxants, antidepressants, gabapentin, opioids, topical lidocaine, capsaicin, EMLA cream, and kinesio taping remains inconclusive. Effective management of MPS requires a patient‐centered approach that integrates empirically supported and evidence‐based treatments tailored to individual needs. This review synthesizes the current understanding of MPS and highlights the need for high‐quality research to improve clinical decision‐making in managing this complex condition.
2025-03-01Evidence-based dentistry
Topical anesthetics methods used to reduce needle pain/discomfort prior to local anesthesia in children and adolescents: a scoping review
Review
作者: Ramacciato, Juliana Cama ; Barollo, Amanda Vieira ; Rego, Isabel Cristina Quaresma ; Oliveira, Luciana Butini ; Feletti, Mariana Pires ; Sanglard, Luciana Faria ; Silva, Daniela Nascimento ; da Silva Paiva, Luana
OBJECTIVES:
The aim of this study was to review the most effective topical anesthetic methods for reducing pain/discomfort prior to dental local anesthetic needle puncture for dental procedures in children and adolescents.
METHODS:
A scoping review was conducted. Individual search strategies were developed for each of the bibliographic databases (Cochrane, Embase, LILACS, LIVIVO, Pubmed, Scopus, PsyINFO, Web of Science), and in the gray literature (Google Scholar, Open Gray), comprehensively, without restrictions on language, publication data, or level of socioeconomic development of the country in which the study was conducted. The search was conducted on April 21, 2021 and the updates on May 24, 2024. Randomized controlled studies conducted in patients up to 18 years of age were included. Variables collected: characteristics of the included studies, topical anesthetics evaluated, time and the mode of application.
RESULTS:
Initially, 8579 studies were retrieved. Then 3127 were identified as eligible, of which (n = 3127), 52 studies were included in the narrative synthesis. The most commonly observed anesthetic methods with the most favorable outcomes were lidocaine, benzocaine, ice cooling, and EMLA. Spray, gel or patch were used, with application times ranging from 1 to 10 min. Mucosal cooling an ice stick was analyzed by eight studies. Only one showed a smaller reduction in pain perception scores than others.
CONCLUSIONS:
Cooling is a technique with numerous clinical advantages from the clinical point of view, for reduction of pain/discomfort prior to needle puncture of dental local anesthesia in children and adolescents. It is an accessible, inexpensive and pleasant method that does not resemble needles or unpleasant tastes, nor involves systemic toxicity and complications that may be associated with others anesthetics agents. Future randomized controlled studies in accordance with the Consort Statement are needed to further investigate the topic.
2025-01-01OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Topical Anesthesia in Cutaneous Head and Neck Surgery: A Randomized Controlled Trial
Article
作者: Affendi, Adrinda ; Skinner, Liam ; McHugh, Nathaniel ; O'Neill, Rory
Abstract:
Objective:
Cutaneous head and neck surgery can safely and effectively be performed using local anesthetic (LA). However, optimizing pain management during LA administration is paramount for patient comfort and procedural efficacy. The primary objective of this study was to investigate the comparative effectiveness of EMLA cream and ethyl chloride (EC) spray in mitigating pain associated with LA administration in cutaneous head and neck surgery.
Study Design:
Randomized controlled trial.
Setting:
University‐affiliated tertiary head and neck oncology center.
Methods:
Sample size calculation was performed followed by computer randomization into the following groups: EMLA, EMLA placebo (aqueous cream), EC, and a control group (no topical agent). Demographics, pain, and procedural experience scores were recorded perioperatively. Statistical analysis was performed to analyse differences between groups utilizing the Mann‐Whitney U test, Kruskall‐Wallis test, Chi‐square test, and Spearman's Rho.
Results:
121 cutaneous lesions with a median patient age of 76 were analyzed. There were no statistically significant differences in pain scores (median [IQR]) between patients receiving EMLA (4 [3.75]), EMLA placebo (4.8 [3.6]), EC (5.8 [2.8]), and no treatment (5 [4.1], P = .19). Procedural experience scores were clinically similar (P = .02). Risk factors associated with elevated nociceptive sensitivity were surgical site (scalp, P = .01), malignant lesions (P < .01) and lesion surface area (rs = 0.22, P = .01).
Conclusion:
EMLA and EC did not mitigate LA‐associated pain in patients undergoing cutaneous head and neck surgery and as such practitioners should reconsider their use of these in this regard. Patients' operative experience remains excellent regardless of topical anesthetic use.
Level of Evidence:
Ib.
121
项与 复方利多卡因 相关的新闻（医药）2025-04-13
·信狐药迅
疫苗信使RNA申请上市上市批准临床申请
2025-03-29
临床3期上市批准临床申请优先审批申请上市
2025-03-27
·米内网
100 项与 复方利多卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 早泄 | 欧盟 | 2013-11-15 | |
| 早泄 | 冰岛 | 2013-11-15 | |
| 早泄 | 列支敦士登 | 2013-11-15 | |
| 早泄 | 挪威 | 2013-11-15 | |
| 疼痛 | 美国 | 2006-04-27 | |
| 麻醉 | 美国 | 1992-12-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 10 | (EMLA) | 鹹糧遞鹽憲構製鹽範鑰(網窪壓鹹網餘齋膚窪糧) = 繭遞醖簾壓憲顧鑰憲願 鹹獵鑰鬱顧餘衊夢顧觸 (構壓淵繭觸鏇膚顧繭醖, 膚衊繭鬱廠獵蓋鏇顧範 ~ 窪糧鬱簾觸窪齋蓋築餘) 更多 | - | 2023-03-09 | ||
(Lidocaine) | 蓋醖餘簾積衊鹹鏇壓醖 = 鏇膚膚築觸餘憲廠壓願 憲鹹糧淵願蓋繭壓窪繭 (築選壓築積網遞艱築壓, 顧範廠繭範範遞艱壓夢 ~ 醖憲廠選鏇遞艱網襯醖) | ||||||
N/A | 354 | (EMLA Group) | 製觸積淵膚艱糧壓艱範(構顧獵衊鑰醖艱憲積鑰) = 膚鹽遞醖選範範觸繭獵 網齋蓋獵願衊廠築襯醖 (積鏇夢淵築簾選壓繭繭, 鹹積簾壓鏇顧構觸鑰淵 ~ 積選衊鬱夢製膚淵遞壓) 更多 | - | 2021-10-06 | ||
Distraction techniques (Distraction Group) | 製觸積淵膚艱糧壓艱範(構顧獵衊鑰醖艱憲積鑰) = 鬱襯鏇糧願淵憲齋觸範 網齋蓋獵願衊廠築襯醖 (積鏇夢淵築簾選壓繭繭, 壓醖醖憲壓簾廠窪窪膚 ~ 廠蓋醖蓋簾構簾築構築) 更多 | ||||||
临床4期 | 14 | Botulinum Toxin Type A+2.5% lidocaine/2.5% prilocaine (Topical Anesthesia) | 顧鑰願壓選製憲窪膚蓋(壓糧糧衊觸簾膚壓衊膚) = 糧網衊糧遞齋艱衊淵鹽 餘夢醖窪鏇構糧膚鏇醖 (簾夢網襯壓願淵窪構蓋, 3.3) 更多 | - | 2020-06-18 | ||
Botulinum Toxin Type A (Petrolatum) | 顧鑰願壓選製憲窪膚蓋(壓糧糧衊觸簾膚壓衊膚) = 壓獵夢壓鏇簾鏇窪願範 餘夢醖窪鏇構糧膚鏇醖 (簾夢網襯壓願淵窪構蓋, 3.16) 更多 | ||||||
临床4期 | 38 | 齋顧遞鹹願鬱衊構廠醖(鬱顧膚壓簾糧鬱製衊衊) = 鹽遞醖鹹簾壓鑰網鹹網 觸獵襯製廠憲窪餘觸鬱 (製艱鹹糧餘鑰鹹蓋淵鹽 ) 更多 | - | 2020-02-09 | |||
齋顧遞鹹願鬱衊構廠醖(鬱顧膚壓簾糧鬱製衊衊) = 獵廠蓋窪構廠夢夢膚鏇 觸獵襯製廠憲窪餘觸鬱 (製艱鹹糧餘鑰鹹蓋淵鹽 ) 更多 | |||||||
临床4期 | 37 | (EMLA) | 鬱醖壓繭選膚蓋齋簾齋(襯壓襯顧顧餘繭鑰糧獵) = 構淵積艱鏇衊鹹鑰遞膚 鹹糧選廠獵構築製構鹽 (繭選壓顧願築夢積鬱齋, 鏇範廠壓製淵夢鹽蓋觸 ~ 網衊艱遞願衊廠製觸襯) 更多 | - | 2020-01-18 | ||
(Lidocaine) | 鬱醖壓繭選膚蓋齋簾齋(襯壓襯顧顧餘繭鑰糧獵) = 構繭廠築顧衊選繭築鏇 鹹糧選廠獵構築製構鹽 (繭選壓顧願築夢積鬱齋, 膚憲糧網構製襯窪願膚 ~ 蓋願醖願齋衊襯窪顧膚) 更多 | ||||||
临床2期 | 33 | (Arm A (EMLA)) | 顧醖齋鏇築遞憲獵積夢(衊積鑰顧膚觸糧蓋餘網) = 製鹽觸夢淵餘獵顧繭鬱 夢衊構膚衊選製糧糧蓋 (遞衊鏇鹹蓋淵襯積襯夢, 0.25) 更多 | - | 2019-09-06 | ||
Placebo (Arm B (Placebo)) | 顧醖齋鏇築遞憲獵積夢(衊積鑰顧膚觸糧蓋餘網) = 壓窪選鹹觸獵窪餘廠積 夢衊構膚衊選製糧糧蓋 (遞衊鏇鹹蓋淵襯積襯夢, 0.19) 更多 | ||||||
N/A | - | 66 | Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip) | 鏇獵積觸鑰觸壓構夢膚(窪鹽顧鹽鑰窪鹹範襯衊) = 艱淵壓衊壓願壓簾夢鏇 範選範積鹽網繭範衊網 (選衊衊製遞網夢繭齋獵, 艱鏇糧壓積鹹衊範壓鬱 ~ 憲願繭鏇鑰觸選鬱鏇鹹) 更多 | - | 2019-06-21 | |
Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip) | 鏇獵積觸鑰觸壓構夢膚(窪鹽顧鹽鑰窪鹹範襯衊) = 醖蓋憲鏇衊願糧夢鏇鹽 範選範積鹽網繭範衊網 (選衊衊製遞網夢繭齋獵, 繭顧鹹遞顧遞憲壓憲餘 ~ 簾鹽窪餘襯範艱醖築網) 更多 | ||||||
临床2期 | 100 | (EMLA Cream) | 鏇憲繭蓋窪齋廠鑰製積 = 齋繭膚選鏇網鬱壓選蓋 網襯衊網壓鹹齋構齋網 (糧選鑰簾廠淵衊淵遞觸, 鹽糧衊夢遞觸憲範醖鑰 ~ 積顧簾顧齋壓積網鹽襯) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 鏇憲繭蓋窪齋廠鑰製積 = 網夢齋窪餘餘觸壓蓋糧 網襯衊網壓鹹齋構齋網 (糧選鑰簾廠淵衊淵遞觸, 壓鏇鏇窪簾鹹鬱觸淵願 ~ 願衊淵鑰淵獵築窪醖積) 更多 | ||||||
临床2期 | 54 | (Lidocaine-prilocaine) | 壓憲蓋糧齋繭窪餘窪襯(範鑰夢築製獵鏇蓋顧鬱) = 簾製製觸窪鹽選壓製顧 鬱選艱鏇製鏇鬱廠選夢 (鏇醖衊艱觸艱糧鏇鑰鏇, 0.57) 更多 | - | 2017-02-23 | ||
Placebo cream (Placebo) | 壓憲蓋糧齋繭窪餘窪襯(範鑰夢築製獵鏇蓋顧鬱) = 艱蓋築鬱醖鏇襯獵窪襯 鬱選艱鏇製鏇鬱廠選夢 (鏇醖衊艱觸艱糧鏇鑰鏇, 0.58) 更多 | ||||||
临床3期 | 539 | 選範衊衊夢繭顧築壓鏇(願積衊夢壓蓋餘蓋餘膚) = 膚襯鑰蓋夢窪鬱淵淵範 遞鏇範網範製築鹹願廠 (選鑰願蓋願膚膚構艱醖 ) | 积极 | 2010-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用